Sumitomo Dainippon Pharma obtains Approval in Japan for Partial Change of the Approved Indication to “Type 2 Diabetes” for SUREPOST, a Rapid-acting Insulin Secretagogue
Posted Video for Second Quarter Financial Results for FY2014 [Webcast]
Sumitomo Dainippon Pharma Announces Organizational Realignment, and Changes in Executive Officers and Other Key Positions
"Corporate profile" An English version and a Japanese version are updated.
Presentation Material (Second Quarter Financial Results for FY2014)
Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2015
A Message from the President
Board of Directors and Executive Officers